Toronto biopharma company that uses large language models to identify failed drug candidates worth reviving, then runs its own clinical trials to bring them to approval for new indications.
Canadian innovation builds a brighter tomorrow.
Toronto biopharma company that uses large language models to identify failed drug candidates worth reviving, then runs its own clinical trials to bring them to approval for new indications.
Federal corporation Biossil Inc. (incorporated 2023-03-31) and Biossil Labs Inc. (incorporated 2026-06-18), both status Active with registered office in Toronto, Ontario. ised-isde.canada.ca
Raised a US$43 million financing round announced April 21, 2026, co-led by Founders Fund and OpenAI, bringing total equity raised to roughly $70 million USD. osler.com
Earlier raised a $3.7 million seed round in 2023 led by Staircase Ventures with Golden Ventures and Panache Ventures, and a US$22 million round in 2024 led by Founders Fund. thelogic.co
Total equity raised to date is about $70M USD from investors including OpenAI, Founders Fund, Modern Capital, Staircase Ventures, Golden Ventures, Panache Ventures and 137 Ventures. betakit.com
Partnered with 20+ universities and research hospitals, including the Hospital for Sick Children, Harvard University, Mayo Clinic and Aarhus University, to source and test failed drugs. theglobeandmail.com
Products Biossil publishes on its own site. Each card links to the page it was taken from.
AI drug discovery & repositioning
Company describes using OpenAI's large language models to convert textual descriptions of failed drug molecules and disease genes into numerical vectors, mapping distances between them (GEMOD analysis) to identify which abandoned drugs show promise against specific disease traits.
Learn more SourceAnnounced rounds only, newest first. Undisclosed amounts are shown as undisclosed.
Apr 21, 2026
Investors: Founders Fund, OpenAI
Government support actually received. Unpublished amounts are left out.
Industrial Research Assistance Program – Contributions to Firms, National Research Council Canada — contribution
Biossil emerged from stealth announcing roughly $70M USD raised to date, including a new US$43M round co-led by Founders Fund and OpenAI, to advance its pipeline of revived drug candidates including active clinical trials for sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer and Alzheimer's disease.
Sourced from the company's own pages or announcements.
Anthony Mouchantaf
Co-Founder & Chief Executive Officer
Dr. Alexander Mosa
Co-Founder & Chief Scientific Officer
Terms the company uses about its own work.
Other companies in Biotechnology & Life Sciences.
Discover companies, track funding, explore career opportunities and stay informed about Canada’s growing tech ecosystem.
